{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:04:27Z","timestamp":1790874267658,"version":"4.1.0"},"reference-count":44,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15873","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:24:07Z","timestamp":1789730647000},"page":"1-9","source":"Crossref","is-referenced-by-count":0,"title":["Decitabine induces cell differentiation and growth inhibition accompanied by upregulation of microRNA\u2011143 and MS4A3 in the myelodysplastic syndromes\u2011derived leukemic cell line MDS\u2011L"],"prefix":"10.3892","volume":"32","author":[{"given":"Rie","family":"Nishi","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Fukui 910\u20111193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Hosono","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Fukui 910\u20111193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Thoyama","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Kawasaki Medical School, Kurashiki, Okayama 701\u20110192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Fukui 910\u20111193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"key20261001193013_b1-ol-32-5-15873","article-title":"SEER*Explorer: An interactive website for SEER cancer statistics","author":"National Cancer Institute and Surveillance Epidemiology, End Results Program"},{"key":"key20261001193013_b2-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1093\/jnci\/djn349","article-title":"Characteristics of US patients with myelodysplastic syndromes: Results of six cross-sectional physician surveys","volume":"100","author":"Sekeres","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"key20261001193013_b3-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1182\/hematology.2021000257","article-title":"Allogeneic hematopoietic cell transplantation for older patients","volume":"2021","author":"Lin","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"key20261001193013_b4-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1002\/cncr.25774","article-title":"Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes","volume":"117","author":"Silverman","year":"2011","journal-title":"Cancer"},{"key":"key20261001193013_b5-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","article-title":"Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: Final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group","volume":"29","author":"L\u00fcbbert","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20261001193013_b6-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1038\/sj.onc.1205699","article-title":"5-Azacytidine and 5-aza-2\u2032-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy","volume":"21","author":"Christman","year":"2002","journal-title":"Oncogene"},{"key":"key20261001193013_b7-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/biom7010003","article-title":"DNA methylation targeting: The DNMT\/HMT crosstalk challenge","volume":"7","author":"Castillo-Aguilera","year":"2017","journal-title":"Biomolecules"},{"key":"key20261001193013_b8-ol-32-5-15873","first-page":"S24","article-title":"A randomized phase II study on the effects of 5-Aza-2\u2032-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: An EORTC Leukemia Cooperative Group phase II study (06893)","volume":"11","author":"Willemze","year":"1997","journal-title":"Leukemia"},{"key":"key20261001193013_b9-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0092-8674(80)90237-8","article-title":"Cellular differentiation, cytidine analogs and DNA methylation","volume":"20","author":"Jones","year":"1980","journal-title":"Cell"},{"key":"key20261001193013_b10-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1053\/j.seminhematol.2005.05.002","article-title":"Pharmacology of 5-Aza-2\u2032-deoxycytidine (decitabine)","volume":"42","author":"Momparler","year":"2005","journal-title":"Semin Hematol"},{"key":"key20261001193013_b11-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1038\/ncponc0354","article-title":"DNA methylation and gene silencing in cancer","volume":"1","author":"Baylin","year":"2005","journal-title":"Nat Clin Pract Oncol"},{"key":"key20261001193013_b12-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1056\/NEJMra023075","article-title":"Gene silencing in cancer in association with promoter hypermethylation","volume":"349","author":"Herman","year":"2003","journal-title":"N Engl J Med"},{"key":"key20261001193013_b13-ol-32-5-15873","first-page":"1324","article-title":"DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias","volume":"87","author":"Leone","year":"2002","journal-title":"Haematologica"},{"key":"key20261001193013_b14-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.3390\/cancers17182953","article-title":"Epigenetic reprogramming by decitabine in triple-negative breast cancer: Mechanisms, immune modulation, and therapeutic synergy","volume":"17","author":"Riyas Mohamed","year":"2025","journal-title":"Cancers (Basel)"},{"key":"key20261001193013_b15-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"4302320","DOI":"10.1155\/2017\/4302320","article-title":"Decitabine-induced changes in human myelodysplastic syndrome cell line SKM-1 are mediated by FOXO3A activation","volume":"2017","author":"Zeng","year":"2017","journal-title":"J Immunol Res"},{"key":"key20261001193013_b16-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"e2300265","DOI":"10.1200\/CCI.23.00265","article-title":"Identification of novel DNA methylation prognostic biomarkers for AML with normal cytogenetics","volume":"8","author":"Cardoso","year":"2024","journal-title":"JCO Clin Cancer Inform"},{"key":"key20261001193013_b17-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"5472893","DOI":"10.1155\/2017\/5472893","article-title":"DNA methylation events as markers for diagnosis and management of acute myeloid leukemia and myelodysplastic syndrome","volume":"2017","author":"Dexheimer","year":"2017","journal-title":"Dis Markers"},{"key":"key20261001193013_b18-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/leu.2011.342","article-title":"DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia","volume":"26","author":"Metzeler","year":"2011","journal-title":"Leukemia"},{"key":"key20261001193013_b19-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3A mutations in acute myeloid leukemia","volume":"363","author":"Ley","year":"2010","journal-title":"N Engl J Med"},{"key":"key20261001193013_b20-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"106372","DOI":"10.1016\/j.leukres.2020.106372","article-title":"DNMT3A alterations associated with myeloid malignancies dictate differential responses to hypomethylating agents","volume":"94","author":"Casellas Roman","year":"2020","journal-title":"Leuk Res"},{"key":"key20261001193013_b21-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"7473","DOI":"10.1073\/pnas.1002650107","article-title":"Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine","volume":"107","author":"Blum","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20261001193013_b22-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/leu.2012.342","article-title":"Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: A novel epigenetic-targeting approach in acute myeloid leukemia","volume":"27","author":"Mims","year":"2013","journal-title":"Leukemia"},{"key":"key20261001193013_b23-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/ajh.21937","article-title":"Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA","volume":"86","author":"Yang","year":"2011","journal-title":"Am J Hematol"},{"key":"key20261001193013_b24-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"key":"key20261001193013_b25-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1172\/JCI78752","article-title":"Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia","volume":"125","author":"Meldi","year":"2015","journal-title":"J Clin Invest"},{"key":"key20261001193013_b26-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.3390\/cells10123494","article-title":"Gene expression profiles identify biomarkers of resistance to decitabine in myelodysplastic syndromes","volume":"10","author":"Kim","year":"2021","journal-title":"Cells"},{"key":"key20261001193013_b27-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2141.1994.tb04904.x","article-title":"Establishment and characterization of a novel myeloid cell line from the bone marrow of a patient with the myelodysplastic syndrome","volume":"87","author":"Tohyama","year":"1994","journal-title":"Br J Haematol"},{"key":"key20261001193013_b28-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2-DDct method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key20261001193013_b29-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-015-0124-6","article-title":"EVI1 promotes tumor growth via transcriptional repression of MS4A3","volume":"8","author":"Heller","year":"2015","journal-title":"J Hematol Oncol"},{"key":"key20261001193013_b30-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1172\/JCI0214025","article-title":"Human HTm4 is a hematopoietic cell cycle regulator","volume":"109","author":"Donato","year":"2002","journal-title":"J Clin Invest"},{"key":"key20261001193013_b31-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1038\/onc.2008.474","article-title":"Role of miR-143 targeting KRAS in colorectal tumorigenesis","volume":"28","author":"Chen","year":"2009","journal-title":"Oncogene"},{"key":"key20261001193013_b32-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"F121","DOI":"10.1152\/ajprenal.00313.2022","article-title":"The miR-143\/145 cluster induced by TGF-beta1 suppresses Wilms' tumor 1 expression in cultured human podocytes","volume":"325","author":"Tabei","year":"2023","journal-title":"Am J Physiol Renal Physiol"},{"key":"key20261001193013_b33-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1634\/theoncologist.2012-0465","article-title":"Concise drug review: Azacitidine and decitabine","volume":"18","author":"Derissen","year":"2013","journal-title":"Oncologist"},{"key":"key20261001193013_b34-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1582-4934.2009.00925.x","article-title":"Characterization of the expression of HTm4 (MS4A3), a cell cycle regulator, in human peripheral blood cells and normal and malignant tissues","volume":"15","author":"Kutok","year":"2011","journal-title":"J Cell Mol Med"},{"key":"key20261001193013_b35-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s10735-004-3913-8","article-title":"The cell cycle associated protein, HTm4, is expressed in differentiating cells of the hematopoietic and central nervous system in mice","volume":"36","author":"Kutok","year":"2005","journal-title":"J Mol Histol"},{"key":"key20261001193013_b36-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s12967-023-04106-6","article-title":"MicroRNA-143 acts as a tumor suppressor through Musashi-2\/DLL1\/Notch1 and Musashi-2\/Snail1\/MMPs axes in acute myeloid leukemia","volume":"21","author":"Li","year":"2023","journal-title":"J Transl Med"},{"key":"key20261001193013_b37-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/mt.2011.53","article-title":"MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression","volume":"19","author":"Osaki","year":"2011","journal-title":"Mol Ther"},{"key":"key20261001193013_b38-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s13018-022-03127-z","article-title":"MicroRNA-143 expression inhibits the growth and the invasion of osteosarcoma","volume":"17","author":"Zhang","year":"2022","journal-title":"J Orthop Surg Res"},{"key":"key20261001193013_b39-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.canlet.2011.04.005","article-title":"MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells","volume":"307","author":"Noguchi","year":"2011","journal-title":"Cancer Lett"},{"key":"key20261001193013_b40-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"11432","DOI":"10.1038\/s41598-022-15263-x","article-title":"Hsa-miR-143-3p inhibits Wnt-beta-catenin and MAPK signaling in human corneal epithelial stem cells","volume":"12","author":"Kalaimani","year":"2022","journal-title":"Sci Rep"},{"key":"key20261001193013_b41-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.leukres.2009.09.014","article-title":"Clinical correlation of circulating heat shock protein 70 in acute leukemia","volume":"34","author":"Yeh","year":"2010","journal-title":"Leuk Res"},{"key":"key20261001193013_b42-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.3390\/cancers3022050","article-title":"Wnt\/\u03b2-catenin signaling in normal and cancer stem cells","volume":"3","author":"Valkenburg","year":"2011","journal-title":"Cancers (Basel)"},{"key":"key20261001193013_b43-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1182\/blood.V100.8.2957","article-title":"Demethylation of a hypermethylated P15\/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2\u2032-deoxycytidine (decitabine) treatment","volume":"100","author":"Daskalakis","year":"2002","journal-title":"Blood"},{"key":"key20261001193013_b44-ol-32-5-15873","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00277-005-0013-0","article-title":"Decitabine activates specific caspases downstream of p73 in myeloid leukemia","volume":"84","author":"Tamm","year":"2005","journal-title":"Ann Hematol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:30:24Z","timestamp":1790872224000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9,18]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15873","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]}}}